[go: up one dir, main page]

PE20180657A1 - Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos - Google Patents

Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos

Info

Publication number
PE20180657A1
PE20180657A1 PE2018000092A PE2018000092A PE20180657A1 PE 20180657 A1 PE20180657 A1 PE 20180657A1 PE 2018000092 A PE2018000092 A PE 2018000092A PE 2018000092 A PE2018000092 A PE 2018000092A PE 20180657 A1 PE20180657 A1 PE 20180657A1
Authority
PE
Peru
Prior art keywords
immunogenic compositions
kits
antigens
sacred
compositions including
Prior art date
Application number
PE2018000092A
Other languages
English (en)
Inventor
Wendy Jo Watson
Martin-Montalvo Luis Pascual Jodar
Raul Enrique Isturiz
Ralf Rene Reinert
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56507633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180657(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PE20180657A1 publication Critical patent/PE20180657A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a nuevas composiciones inmunogenas que comprenden antigenos de sacarido capsular de Streptococcus pneumoniae conjugados (glucoconjugados), kits que comprenden tales composiciones inmunogenas y sus usos. En general, las composiciones inmunogenas de la presente invencion comprenden al menos un glucoconjugado de un serotipo de S. pneumoniae no encontrado en PREVNAR®, SYNFLORIX® y/o PREVNAR 13®. La invencion tambien se refiere a la vacunacion de sujetos humanos, en particular, ninos y personas mayores, contra infecciones neumococicas usando tales composiciones inmunogenas novedosas.
PE2018000092A 2015-07-21 2016-07-18 Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos PE20180657A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562194965P 2015-07-21 2015-07-21

Publications (1)

Publication Number Publication Date
PE20180657A1 true PE20180657A1 (es) 2018-04-17

Family

ID=56507633

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2018000092A PE20180657A1 (es) 2015-07-21 2016-07-18 Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
PE2023001198A PE20240927A1 (es) 2015-07-21 2016-07-18 Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2023001198A PE20240927A1 (es) 2015-07-21 2016-07-18 Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos

Country Status (23)

Country Link
US (4) US10124050B2 (es)
EP (2) EP3325008B1 (es)
JP (4) JP6994453B2 (es)
KR (4) KR102800419B1 (es)
CN (1) CN108367063A (es)
AR (1) AR105402A1 (es)
AU (2) AU2016295566B2 (es)
BR (1) BR112018000087A2 (es)
CA (1) CA2936378A1 (es)
CO (1) CO2018000503A2 (es)
ES (1) ES3050314T3 (es)
HK (1) HK1257816A1 (es)
IL (2) IL303998A (es)
MX (2) MX388869B (es)
MY (1) MY192183A (es)
NZ (1) NZ739007A (es)
PE (2) PE20180657A1 (es)
PH (1) PH12018500037A1 (es)
RU (1) RU2721128C2 (es)
SG (1) SG10202005253TA (es)
TW (4) TWI684461B (es)
WO (1) WO2017013548A1 (es)
ZA (2) ZA201800197B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DK3096786T3 (da) * 2014-01-21 2021-08-02 Pfizer Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf
ES2883343T3 (es) 2014-01-21 2021-12-07 Pfizer Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
BR112018000087A2 (pt) * 2015-07-21 2018-09-04 Pfizer Inc. composições imunogênicas que compreendem antígenos de sacarídeos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas
CA3005524C (en) * 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP3436061A4 (en) 2016-03-31 2019-12-04 Liffey Biotech Limited Saccharide-polypeptide-conjugate compositions and methods of use thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11998599B2 (en) 2016-12-30 2024-06-04 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3576784B1 (en) 2017-01-31 2025-09-24 Merck Sharp & Dohme LLC Methods for making polysaccharide-protein conjugates
WO2018144799A1 (en) 2017-02-03 2018-08-09 SCHADECK, Eva, Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
EP3589314A4 (en) * 2017-02-24 2021-04-21 Merck Sharp & Dohme Corp. INCREASED IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE PROTEIN CONJUGATES
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
KR20240018697A (ko) 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
MX2020002559A (es) * 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
EP3678653A4 (en) 2017-09-07 2021-05-26 Merck Sharp & Dohme Corp. PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE CARRIER PROTEIN CONJUGATES
EP3678654B1 (en) * 2017-09-07 2024-06-26 Merck Sharp & Dohme LLC Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
BR112020004410A8 (pt) * 2017-09-07 2023-01-31 Merck Sharp & Dohme Processos para a formulação de polissacarídeos pneumocócicos para conjugação a uma proteína carreadora
EP3678652A4 (en) * 2017-09-07 2021-05-19 Merck Sharp & Dohme Corp. PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE CARRIER PROTEIN CONJUGATES
EP3691677A4 (en) * 2017-10-04 2021-07-07 Pogona, Llc COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
CN117982633A (zh) 2017-12-06 2024-05-07 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
CN120661645A (zh) 2018-04-30 2025-09-19 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
JP7489324B2 (ja) * 2018-04-30 2024-05-23 メルク・シャープ・アンド・ドーム・エルエルシー リオスフィアから肺炎連鎖球菌莢膜多糖類キャリアタンパク質コンジュゲートを生産する方法
CA3111459A1 (en) 2018-09-12 2020-03-19 Affinivax, Inc. Multivalent pneumococcal vaccines
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
CN110302375A (zh) * 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
CN112741901B (zh) * 2019-10-31 2024-05-10 北京科兴中维生物技术有限公司 一种含有5型肺炎链球菌荚膜多糖的疫苗及其制备方法
JP2023503086A (ja) * 2019-11-22 2023-01-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細菌サッカリド複合糖質ワクチンの用法及び用量
WO2021229604A1 (en) * 2020-05-14 2021-11-18 Serum Institute Of India Private Limited Methods for simultaneous fragmentation and purification of bacterial polysaccharides
EP4192499A4 (en) 2020-08-10 2024-09-25 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
IL311239A (en) 2021-09-09 2024-05-01 Affinivax Inc Multivalent pneumococcal vaccines
WO2023051684A1 (zh) * 2021-09-29 2023-04-06 北京大学 一种细菌荚膜寡糖衍生物及其制备方法、药物组合物和用途
GB2614916A (en) * 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
CN115671274B (zh) * 2022-09-29 2024-03-12 普大生物科技(泰州)有限公司 一种载体蛋白与多糖共价键连接成结合物的方法及应用
JP2025535291A (ja) * 2022-11-07 2025-10-24 サウスウエスト リサーチ インスティテュート 野兎病に対する、凍結乾燥及び安定化された製剤化弱毒化生ワクチン
WO2025219904A1 (en) * 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
EP0625910B1 (en) 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993021769A1 (en) 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
UA40597C2 (uk) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
CN1087176C (zh) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
KR100376361B1 (ko) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
US5416349A (en) 1993-12-16 1995-05-16 National Semiconductor Corporation Increased-density flash EPROM that requires less area to form the metal bit line-to-drain contacts
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
NZ506603A (en) 1998-04-09 2002-10-25 Smithkline Beecham Biolog S Adjuvant compositions comprising polyoxyethylene ether or polyoxyethylene ester
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
JP2003519084A (ja) 1998-10-16 2003-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
EP1140157B1 (en) 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
AU1764900A (en) 1998-12-23 2000-07-31 Id Biomedical Corporation Novel streptococcus antigens
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
EP1880735A3 (en) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AU764969B2 (en) 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
CZ20021043A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NZ553554A (en) 2000-06-20 2008-11-28 Id Biomedical Corp Streptococcus antigens
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1456231A2 (en) 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
EP1601689B1 (en) 2003-03-13 2007-11-28 GlaxoSmithKline Biologicals S.A. Purification process for bacterial cytolysin
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
AU2005335104C1 (en) 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
WO2006134423A2 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
AU2006235013B2 (en) 2005-04-08 2011-11-03 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2808126T3 (es) 2005-04-08 2021-02-25 Wyeth Llc Separación de contaminantes de polisacárido de Streptococcus pneumoniae por manipulación del pH
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
PE20070163A1 (es) * 2005-06-27 2007-03-01 Glaxosmithkline Biolog Sa Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
EP3020411A1 (en) * 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CL2007002909A1 (es) 2006-10-10 2008-04-18 Wyeth Corp Metodo para reduccion o extraccion de impurezas de proteinas a partir de lisado celular de streptoccocus pneumoniae que comprende calentar dicho lisado, separar a los precipitantes a partir de dicho lisado produciendo un lisado que contiene polisacar
ES2922132T3 (es) 2007-03-23 2022-09-08 Wyeth Llc Procedimiento abreviado de purificación para la producción de polisacáridos capsulares de Streptococcus pneumoniae
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2008157590A1 (en) 2007-06-20 2008-12-24 Baxter International Inc. Modified polysaccharides for conjugate vaccines
MX2009013949A (es) * 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
CN102413838A (zh) 2009-04-30 2012-04-11 科勒制药集团有限公司 肺炎球菌疫苗及其用途
BRPI1011753B8 (pt) * 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101785857B (zh) 2010-03-05 2012-09-26 成都安特金生物技术有限公司 一种新的肺炎球菌结合疫苗及其制备方法
WO2011130332A1 (en) * 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2648506A1 (en) * 2010-12-10 2013-10-16 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
JP5944480B2 (ja) * 2011-03-22 2016-07-05 セルム・インスティテュート・オブ・インディア・ピーブイティー．・リミテッド 多糖を調製するための新規な方法
US20150132339A1 (en) * 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
MY167579A (en) * 2012-08-16 2018-09-20 Pfizer Glycoconjugation processes and compositions
CN103656631B (zh) * 2012-09-24 2015-08-19 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法
GB201218660D0 (en) * 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
KR20150072444A (ko) * 2012-10-17 2015-06-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 하나 이상의 스트렙토코커스 뉴모니애 캡슐 사카라이드 컨쥬게이트 및 해모필루스 인플루엔자로부터의 단백질 Ｅ 및／또는 ＰｉｌＡ를 포함하는 단백질 성분을 포함하는 면역원성 조성물
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2014097099A2 (en) * 2012-12-20 2014-06-26 Pfizer Inc. Glycoconjugation process
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
US20150079132A1 (en) * 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
CN103495161B (zh) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
DK3096786T3 (da) * 2014-01-21 2021-08-02 Pfizer Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf
ES2883343T3 (es) * 2014-01-21 2021-12-07 Pfizer Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
SG11201604728XA (en) * 2014-01-21 2016-08-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10668164B2 (en) * 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
EP3197907B1 (en) * 2014-09-26 2019-09-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccines against streptococcus pneumoniae serotype 8
MX395525B (es) * 2015-01-15 2025-03-25 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
US10716839B2 (en) * 2015-04-13 2020-07-21 University Of Maryland, Baltimore Compositions and methods for producing bacterial conjugate vaccines
PL3313436T3 (pl) * 2015-06-23 2021-06-14 Biological E Limited Wielowartościowa skoniugowana szczepionka przeciw pneumokokom
BR112018000087A2 (pt) * 2015-07-21 2018-09-04 Pfizer Inc. composições imunogênicas que compreendem antígenos de sacarídeos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas
WO2017220753A1 (en) * 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
CN109862908B (zh) * 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US11998599B2 (en) * 2016-12-30 2024-06-04 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
BR112019014833A2 (pt) * 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
EP3589314A4 (en) * 2017-02-24 2021-04-21 Merck Sharp & Dohme Corp. INCREASED IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE PROTEIN CONJUGATES
CN110392690B (zh) * 2017-02-24 2024-01-30 默沙东有限责任公司 肺炎球菌缀合物疫苗制剂
KR102101879B1 (ko) * 2017-03-15 2020-05-29 주식회사 엘지화학 다가 폐렴구균 백신 조성물
KR20240018697A (ko) * 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
EP3691677A4 (en) * 2017-10-04 2021-07-07 Pogona, Llc COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
CN117982633A (zh) * 2017-12-06 2024-05-07 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法

Also Published As

Publication number Publication date
TWI756893B (zh) 2022-03-01
CA2936378A1 (en) 2017-01-21
IL256645A (en) 2018-02-28
JP6994453B2 (ja) 2022-01-14
ZA201800197B (en) 2021-04-28
EP3325008A1 (en) 2018-05-30
AU2019208271A1 (en) 2019-08-15
RU2018100123A (ru) 2019-08-21
AU2016295566B2 (en) 2019-06-20
WO2017013548A1 (en) 2017-01-26
CN108367063A (zh) 2018-08-03
TWI684460B (zh) 2020-02-11
TWI720448B (zh) 2021-03-01
SG10202005253TA (en) 2020-07-29
US20170021006A1 (en) 2017-01-26
RU2721128C2 (ru) 2020-05-18
US20250009864A1 (en) 2025-01-09
US10124050B2 (en) 2018-11-13
RU2018100123A3 (es) 2019-08-21
IL303998A (en) 2023-08-01
US20210260177A1 (en) 2021-08-26
TWI684461B (zh) 2020-02-11
TW202003022A (zh) 2020-01-16
MX2021015775A (es) 2022-01-31
TW201822814A (zh) 2018-07-01
ES3050314T3 (en) 2025-12-19
TW202108167A (zh) 2021-03-01
EP3325008B1 (en) 2025-09-10
PH12018500037A1 (en) 2018-07-09
EP4649956A2 (en) 2025-11-19
HK1257816A1 (zh) 2019-11-01
US20190070282A1 (en) 2019-03-07
NZ739007A (en) 2022-08-26
JP2018524380A (ja) 2018-08-30
CO2018000503A2 (es) 2018-06-12
MX2018000867A (es) 2018-05-15
JP2023093636A (ja) 2023-07-04
JP2022037092A (ja) 2022-03-08
MX388869B (es) 2025-03-20
MY192183A (en) 2022-08-05
US11020469B2 (en) 2021-06-01
KR102800419B1 (ko) 2025-04-25
KR20210027523A (ko) 2021-03-10
TW201718005A (zh) 2017-06-01
KR102225282B1 (ko) 2021-03-10
BR112018000087A2 (pt) 2018-09-04
AR105402A1 (es) 2017-09-27
KR20230058726A (ko) 2023-05-03
JP7268125B2 (ja) 2023-05-02
PE20240927A1 (es) 2024-04-30
JP2025122002A (ja) 2025-08-20
AU2019208271B2 (en) 2021-11-18
ZA201903620B (en) 2021-04-28
KR20180030175A (ko) 2018-03-21
AU2016295566A1 (en) 2018-01-18
KR20250058066A (ko) 2025-04-29

Similar Documents

Publication Publication Date Title
PE20180657A1 (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
CO2017011245A2 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
BR112018007812A2 (pt) polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica.
HK1224300A1 (zh) 合成针对1型肺炎链球菌的疫苗
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
MX2019002552A (es) Composicion que comprende polisacarido capsular neumococico multivalente-proteina transportadora y uso de la misma.
WO2022101745A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3010537A1 (en) Vaccine strains of brachyspira hyodysenteriae
AR132428A1 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y usos de estos
CO2025006472A2 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y sus usos
CO2025013417A2 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y usos de estos
CO2025014261A2 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y usos de estos
PE20251701A1 (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
AR104514A1 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos